Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.

January 9, 2009

CHICAGO and PHOENIX, Jan. 9 /PRNewswire/ — Houlihan Smith & Co., Inc.
acted as the exclusive advisor in arranging a non-control equity investment
into Sottera, Inc. d/b/a NJOY, as announced by Charles Botchway, Group
Managing Director and Vice Chairman of Houlihan Smith & Company, Inc. The
transaction was led by Houlihan Smith Managing Director Reginald McGaugh.
Terms were not disclosed.

“We appreciate the process management and financial advisory services
provided by Reginald McGaugh and his team at Houlihan Smith & Company, Inc.
related to this equity investment,” said Jack Leadbeater, CEO of Sottera. “We
look forward to continuing our capital-raising process with Mr. McGaugh and
his team as we continue our international growth.”

“This investment represents a significant opportunity for NJOY to achieve
growth initiatives related to its revolutionary product,” said McGaugh, who
worked directly with NJOY to establish the equity investment. “The facility
will be used to support the continued growth of NJOY based on recently signed
distribution agreements in North America, South America, and Asia.”

Based in Scottsdale, Arizona, Sottera has filed for patents to manufacture
and distribute groundbreaking products and technology represented by the
trademarked brand NJOY (http://www.njoy.com). The name Sottera is derived
from Soteria, the Greek god of preservation, redemption and salvation. These
three words are the essence of the NJOY brand and products, which give tobacco
users the opportunity to continue smoking with greater freedom, lower cost and
more social acceptance. NJOY is currently being sold in all 50 states and in
more than 25 foreign countries. NJOY is available online at
http://www.njoy.com for shipment around the globe, and is also available on
affiliated websites and at retail locations across the U.S.

Miri Pharma, Inc. is a division of Canderm Pharma, Inc. Canderm Pharma,
Inc. develops and sells cosmeceuticals, over-the-counter (OTC) skin care
products, and dermatological items. Its product line includes ArtteSense,
Betacaine, Cliniderm, Lipsorex, NeoStrata, Rosacure, and Ultraquin, as well as
Condyline Topical Solution, Dermagran II, Epi-Derm, and UltraMOP. The firm
also sells Ayria, a skin care line sold exclusively through dermatologists,
and distributes Radiesse, produced by BioForm Medical, a trendy injectable
filler alternative to facelifts.

Houlihan Smith & Company, Inc. (“Houlihan”) is a specialized investment
banking firm that provides advisory, financing, and valuation services to
public and private businesses. Houlihan is a registered broker-dealer and

Houlihan understands the time sensitivity of corporate finance, and
responds quickly and tenaciously to opportunities. The Houlihan approach
creates corporate finance transactions in which business owners and investors
mutually benefit. We have the knowledge, experience and relationships to match
buyers and sellers, as well as to match the appropriate financing and
capitalization structure to each unique client situation. The Houlihan name
is synonymous with professional financial expertise. We provide
cost-effective fairness and solvency opinions, as well as valuations for tax
and financial reporting, to some of the largest NYSE/NASDAQ companies, as well
as small, privately held businesses. (http://www.houlihansmith.com)

     Rebecca Carriere

SOURCE Houlihan Smith & Co., Inc.

Source: newswire

comments powered by Disqus